Inflammatory bowel disease is a term for two conditions, ulcerative colitis and Crohn's disease, that are characterized by excessive activation of the immune response in the intestinal mucosa, in which the IL-23/Th17 axis plays an important role. The disease is treated systemically with aminosalicylates, immunosuppressants, corticosteroids and, in the most severe forms, with antibodies against various targets in the process of inflammatory responses. Because antibodies have high prices, many side effects, and they are not effective in a large proportion of patients, development of smaller proteins with high binding affinity, specifity and ability of inhibition was neccesary. In the context of the master's thesis we used recombinant proteins REX009, REX115 and REX125 with a confirmed antagonist activity for the receptor for IL-23 and upgraded them with a targeted delivery. For the delivery system we selected the lactic acid bacterium Lactococcus lactis, because of its GRAS status (generally recognized as safe) and beneficial effects on gut microbiota. We aimed to engineer recombinant L. lactis cells secreting REX proteins into the media, and with the ability to display REX proteins on surface. For the preparation of plasmids with the REX gene construct we used model plasmids pNZ8148, pSDBA3b and pGEM-T Easy. The final plasmids were constructed within the plasmid framework of pSDBA3b, which allows nisin controlled gene expression, with the addeded Usp45 secretion signal, Flag tag, REX protein, and the cAcmA surface anchor. In the process of preparing constructs, gene fragments were amplified with PCR, separated by agarose gel electrophoresis, and inserted into the plasmids by restriction and ligation. Plasmids were analyzed with colony PCR, verified with nucleotide sequencing and introduced into L. lactis. Expression of recombinant proteins was demonstrated with SDS PAGE, Western blot and Commassie Brilliant Blue staining . To evaluate the secretion and the surface display, we used flow cytometry. We confirmed the successful binding of the IL-23 receptor to surface displayed REXs, with the highest binding ability demonstrated for REX125. Furthermore, we investigated the effect of fusion with the Flag peptide, and found a negative effect on the extent of binding. In addition, statistically significant binding of secreted REX009 and REX115 proteins to bacterially produced soluble human IL-23R was confirmed by ELISA.
|